StockWatch
·

Fortress Biotech, Inc. Q2 FY26 Results

FBIOQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue18.7216.7%14.1%
Total Income18.7216.7%14.1%
Expenditure28.7220.8%45.7%
PBT0.9299.3%
Net Profit-0.47100.4%103.0%
OPM-53.46%5.20pp
NPM-2.50%102.50pp96.85pp
EPS-0.08102.3%116.0%
View full financials

Fortress Biotech Reports Q2 2026 Financial Results and Corporate Highlights

14 Aug 2026 · 14 Aug, 1:53 am

Summary

Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for the second quarter of 2026, compared to $16.4 million in the second quarter of 2025. The company's consolidated net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, for the quarter, a shift from a net income of $13.4 million in the prior year. Cash and cash equivalents significantly increased to $196.6 million as of June 30, 2026. Management highlighted continued momentum across the portfolio, including advancements in partnered programs like dotinurad and anselamimab, and expanded payer access for Emrosi®.

Key Highlights

  1. 1

    Total net revenue increased 14% to $18.7 million for the second quarter of 2026 compared to the second quarter of 2025.

  2. 2

    Journey Medical reported net product revenues of $17.8 million for the second quarter of 2026, an increase from $15.0 million in the prior year's second quarter.

  3. 3

    In the second quarter of 2026, Cyprium Therapeutics recognized $0.2 million in royalty revenue on net sales of ZYCUBO®, and Fortress recognized $0.1 million in royalty income on net sales of UNLOXCYT™.

  4. 4

    Fortress' consolidated cash and cash equivalents totaled $196.6 million as of June 30, 2026, an increase of $117.2 million year-to-date.

  5. 5

    Consolidated net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, for the second quarter ended June 30, 2026, compared to a net income of $13.4 million, or $0.50 per share, for the second quarter ended June 30, 2025.

  6. 6

    AstraZeneca reported additional prespecified subgroup analyses for anselamimab showing a 62% improvement in survival and a 71% reduction in cardiovascular hospitalizations among kappa predominant light chain isotype patients.

Management Comments

L

Lindsay A. Rosenwald

The second quarter of 2026 reflected continued momentum across our portfolio and further progress in unlocking long-term shareholder value. Our subsidiary Urica Therapeutics, Inc.’s (“Urica”) equity position in Crystalys Therapeutics, Inc. (“Crystalys”) was strengthened by Crystalys' $130 million Series B financing, which will support the late-stage global development and commercialization preparation for dotinurad, a next-generation oral URAT1 inhibitor for gout, on which Urica is entitled to a 3% royalty on future net sales. Journey Medical also continues to scale Emrosi®, securing a third major GPO contract that expanded payer access to over 150 million commercial lives. Coming off the momentum of ZYCUBO®'s approval and the $205 million PRV sale in the first quarter, we enter the second half of 2026 with a favorable cash balance that positions us to continue executing on our pipeline and business development priorities. We continued to see encouraging clinical progress this quarter on our partnered programs. AstraZeneca reported additional prespecified subgroup analyses for anselamimab (formerly CAEL-101) showing a 62% improvement in survival and a 71% reduction in cardiovascular hospitalizations among kappa predominant light chain isotype patients in the CARES program, and indicated that it plans to submit these findings to regulatory authorities. Crystalys also continues to advance dotinurad's two global Phase 3 trials while initiating a new Phase 2 study in difficult-to-treat gout, broadening the program's potential patient population. With a diversified portfolio spanning commercial, late-stage, and development-stage programs, including royalties, milestones and equity, and a strengthened balance sheet following the ZYCUBO® PRV monetization, we believe Fortress is well positioned to advance strategic initiatives and drive long-term value for our shareholders.

Informational and educational content only. Not investment advice.